Advanced search
Publication Cover
Leukemia & Lymphoma Volume 45, 2004 - Issue 5
Submit an article Journal homepage
87
Views
23
CrossRef citations to date
0
Altmetric
Original Article

Fludarabine, Cyclophosphamide and Mitoxantrone in Relapsed or Refractory Chronic Lymphocytic Leukemia and Low Grade Non-Hodgkin's Lymphoma

L Hendry Academic Department of Haematology and Cytogenetics, The Royal Marsden NHS Trust, Fulham Road, London, SW3 6JJ, UKCorrespondence[email protected]
,
A Bowen Northampton General Hospital NHS Trust, Northampton, UK
,
E Matutes Academic Department of Haematology and Cytogenetics, The Royal Marsden NHS Trust, Fulham Road, London, SW3 6JJ, UK
,
J Swansbury Northampton General Hospital NHS Trust, Northampton, UK
&
D Catovsky Academic Department of Haematology and Cytogenetics, The Royal Marsden NHS Trust, Fulham Road, London, SW3 6JJ, UK
Pages 945-950 | Received 16 Oct 2003, Published online: 03 Aug 2009

Citations (23)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Jeffrey Bryan & Gautam Borthakur. (2011) Role of rituximab in first-line treatment of chronic lymphocytic leukemia. Therapeutics and Clinical Risk Management 7, pages 1-11.
Read now
Leslie A Andritsos & Michael R Grever. (2011) Salvage therapy for relapsed chronic lymphocytic leukemia. Expert Review of Hematology 4:2, pages 199-212.
Read now
Alessandra Tedeschi, Eleonora Vismara, Francesca Ricci, Enrica Morra & Marco Montillo. (2010) The spectrum of use of rituximab in chronic lymphocytic leukemia. OncoTargets and Therapy 3, pages 227-246.
Read now

Articles from other publishers (20)

T Munir, D R Howard, L McParland, C Pocock, A C Rawstron, A Hockaday, A Varghese, M Hamblin, A Bloor, A Pettitt, C Fegan, J Blundell, J G Gribben, D Phillips & P Hillmen. (2017) Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL. Leukemia 31:10, pages 2085-2093.
Crossref
Pau AbrisquetaNeus VillamorMaría José TerolEva González-BarcaMarcos GonzálezChristelle FerràEugenia AbellaJulio DelgadoJose A. García-MarcoYolanda GonzálezFelix CarbonellSecundino FerrerEncarna MonzóIsidro JarqueAna MuntañolaMireia ConstantsLourdes Escoda, Xavier CalvoSabela BobilloJosé Bruno Montoro, Emili MontserratFrancesc Bosch. (2013) Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. Blood 122:24, pages 3951-3959.
Crossref
Valentina Manfè, Edyta Biskup, Ayalah Willumsgaard, Anne Guldhammer Skov, Dario Palmieri, Pierluigi Gasparini, Alessandro Laganá, Anders Woetmann, Niels Ødum, Carlo Maria Croce & Robert Gniadecki. (2013) cMyc/miR-125b-5p Signalling Determines Sensitivity to Bortezomib in Preclinical Model of Cutaneous T-Cell Lymphomas. PLoS ONE 8:3, pages e59390.
Crossref
Gautam Borthakur & Susan O’Brien. 2013. Neoplastic Diseases of the Blood. Neoplastic Diseases of the Blood 103 119 .
Matthew A. Lunning & Julie M. Vose. (2012) Management of indolent lymphoma: Where are we now and where are we going. Blood Reviews 26:6, pages 279-288.
Crossref
Hubert Köppler, Harald Fuss, Hans J. Hurtz, Owe Knigge, Christoph Losem, Daniel Reschke, Stephan Schmitz, Rudolf Weide, Johann Weiß & Michael Hallek. (2012) Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG). British Journal of Haematology 158:2, pages 238-241.
Crossref
Marays VelizJavier Pinilla-Ibarz. (2012) Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia. Cancer Control 19:1, pages 37-53.
Crossref
Peter Hillmen, Dena R. Cohen, Kim Cocks, Andrew Pettitt, Hazem A. Sayala, Andy C. Rawstron, Daniel B. Kennedy, Christopher Fegan, Don W. Milligan, John Radford, Jane Mercieca, Claire Dearden, Raphael Ezekwisili, Alexandra F. Smith, Julia Brown, Gillian A. Booth, Abraham M. Varghese & Christopher Pocock. (2011) A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia. British Journal of Haematology 152:5, pages 570-578.
Crossref
Francesc BoschPau AbrisquetaNeus VillamorMaría José TerolEva González-BarcaChristelle FerraMarcos González DiazEugenia AbellaJulio DelgadoFélix CarbonellJosé Antonio García MarcoLourdes EscodaSecundino FerrerEncarnación MonzóYolanda GonzálezCristina EstanyIsidro JarqueOlga SalameroAna MuntañolaEmili Montserrat. (2009) Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia. Journal of Clinical Oncology 27:27, pages 4578-4584.
Crossref
Marina Motta, William G. Wierda & Alessandra Ferrajoli. (2009) Chronic lymphocytic leukemia. Cancer 115:17, pages 3830-3841.
Crossref
Tahamtan Ahmadi, Tapan Maniar, Stephen Schuster & Edward Stadtmauer. (2009) Chronic Lymphocytic Leukemia: New Concepts and Emerging Therapies. Current Treatment Options in Oncology 10:1-2, pages 16-32.
Crossref
Xiaobin Zhao, Jianmei Wu, Natarajan Muthusamy, John C. Byrd & Robert J. Lee. (2008) Liposomal Coencapsulated Fludarabine and Mitoxantrone for Lymphoproliferative Disorder Treatment**Xiaobin Zhao and Jianmei Wu contributed equally to this study.. Journal of Pharmaceutical Sciences 97:4, pages 1508-1518.
Crossref
Francesc Bosch, Ana Ferrer, Neus Villamor, Marcos González, Javier Briones, Eva González-Barca, Eugenia Abella, Santiago Gardella, Lourdes Escoda, Elena Pérez-Ceballos, Antoni Asensi, Ma José Sayas, Llorenç Font, Albert Altés, Ana Muntañola, Paola Bertazzoni, María Rozman, Marta Aymerich, Eva Giné & Emili Montserrat. (2008) Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication. Clinical Cancer Research 14:1, pages 155-161.
Crossref
Rebecca L. Auer, John Gribben & Finbarr E. Cotter. (2007) Emerging therapy for chronic lymphocytic leukaemia. British Journal of Haematology 139:5, pages 635-644.
Crossref
Paolo Ghia, Andrés J.M. Ferreri & Federico Caligaris-Cappio. (2007) Chronic lymphocytic leukemia. Critical Reviews in Oncology/Hematology 64:3, pages 234-246.
Crossref
M. Leithäuser & M. Freund. 2007. Therapiekonzepte Onkologie. Therapiekonzepte Onkologie 342 384 .
Stefan Faderl, Kanti Rai, John Gribben, John C. Byrd, Ian W. Flinn, Susan O'Brien, Shihong Sheng, Dixie‐Lee Esseltine & Michael J. Keating. (2006) Phase II study of single‐agent bortezomib for the treatment of patients with fludarabine‐refractory B‐cell chronic lymphocytic leukemia. Cancer 107:5, pages 916-924.
Crossref
Nicholas Di Bella & Farhad Ravandi. (2006) Purine Analogue Combinations for Indolent Lymphomas. Seminars in Hematology 43, pages S11-S21.
Crossref
Ladislav Novotny, Peter Rauko, Jan Liska, Howard L. Elford & Thomas Szekeres. (2006) Potentiation of the activity of cisplatin and cyclophosphamide by trimidox, a novel ribonucleotide reductase inhibitor, in leukemia-bearing mice. Cancer Letters 233:1, pages 178-184.
Crossref
. (2004) Current Awareness in Hematological Oncology. Hematological Oncology 22:2, pages 73-84.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.